CGRP is a neuropeptide produced in sensory neurons, known as a potent vasodilator and central to migraine pathophysiology. Researchers study its involvement in pain transmission, neurogenic inflammation, and its therapeutic potential for migraines.
In the literature, CGRP appears most often in work focused on pain research, inflammation and neuroprotection. Studies in this area tend to look at mechanisms and observed effects in laboratory and preclinical settings rather than outcomes in people, so the picture is best read as a map of where researchers have been curious — not as evidence of any benefit.
CGRP is catalogued here under powder peptides. Coverage of this compound varies in quality and depth, and much of it remains early-stage. Reading the underlying research directly is the only way to judge how strong any particular finding is.
Tap a topic to see which peptides are most studied for it.
Alamandine is an endogenous heptapeptide structurally similar to angiotensin 1-7 but acts on a different receptor (MrgD). It is studied for its potential roles in cardiovascular regulation, inflammation, and tissue protection.
An EPO-derived peptide studied for neuropathic pain, small fiber neuropathy, and tissue protection.
A neuropeptide preparation studied for neuroprotection, cognitive function, and recovery after brain injury.
Research use only. This page summarizes areas of published study and is not medical advice. No dosing, protocol, or usage guidance is provided.